No Data
No Data
ProMIS Neurosciences Brief: Says Strengthened Global Intellectual Property Portfolio
07:00 AM EDT, 03/11/2024 (MT Newswires) -- ProMIS Neurosciences Brief: Says Strengthened Global Intellectual Property Portfolio
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic
Express News | ProMIS Neurosciences Has Selected The Lead Vaccine Candidate, PMN400, Against Multiple Synucleinopathies Including Multiple System Atrophy, Parkinson's Disease And Lewy Body Dementia
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic
CRGE and LAES Among Mid-day Movers
No Data